Plus Therapeutics Inc
NASDAQ:PSTV

Watchlist Manager
Plus Therapeutics Inc Logo
Plus Therapeutics Inc
NASDAQ:PSTV
Watchlist
Price: 0.2878 USD -0.76%
Market Cap: 39.6m USD

Operating Margin

-255.9%
Current
Improving
by 980.4%
vs 3-y average of -1 236.4%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-255.9%
=
Operating Income
$-13.5m
/
Revenue
$5.3m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-255.9%
=
Operating Income
$-13.5m
/
Revenue
$5.3m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Plus Therapeutics Inc
NASDAQ:PSTV
38.2m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.6B AUD
Loading...
NL
argenx SE
XBRU:ARGX
40.7B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD
Loading...
No Stocks Found

Market Distribution

Lower than 89% of companies in the United States of America
Percentile
11th
Based on 14 112 companies
11th percentile
-255.9%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Plus Therapeutics Inc
Glance View

Market Cap
39.6m USD
Industry
Biotechnology

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The company is headquartered in Austin, Texas and currently employs 14 full-time employees. The company went IPO on 2000-08-09. The firm is focused on developing treatments for patients battling cancer. The firm provides nanotechnology platform to reformulate and improve workhorse chemotherapeutics to provide benefits to patients and healthcare providers. The firm is focused on developing generic oncology drugs that address unmet medical and market needs. The Company’s lead product candidate, DocePLUS, is an albumin-stabilized PEGylated liposomal formulation of docetaxel. DocePLUS is developed for the treatment of patients with small cell lung cancer (SCLC). The firm is also developing DoxoPLUS, which is a generic PEGylated liposomal formulation of doxorubicin. DoxoPLUS is developed for the treatment of breast cancer, ovarian cancer, multiple myeloma and Kaposi’s sarcoma. The firm also focuses on developing Rhenium-186 NanoLiposome (186RNL) for the treatment of recurrent glioblastoma-a rare, incurable and fatal disease.

PSTV Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-255.9%
=
Operating Income
$-13.5m
/
Revenue
$5.3m
What is Plus Therapeutics Inc's current Operating Margin?

The current Operating Margin for Plus Therapeutics Inc is -255.9%, which is above its 3-year median of -1 236.4%.

How has Operating Margin changed over time?

Over the last 3 years, Plus Therapeutics Inc’s Operating Margin has increased from -25 400% to -255.9%. During this period, it reached a low of -25 400% on Sep 30, 2022 and a high of -195.7% on Mar 31, 2024.

Back to Top